AAAAAA
Results: 1-25/62
Authors:
LANGER CJ
CALVERT P
OZOLS RF
Citation: Cj. Langer et al., GEMCITABINE AND CARBOPLATIN IN COMBINATION - PHASE-I AND PHASE-II STUDIES, Seminars in oncology, 25(4), 1998, pp. 51-54
Authors:
MCGUIRE WP
OZOLS RF
Citation: Wp. Mcguire et Rf. Ozols, CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER, Seminars in oncology, 25(3), 1998, pp. 340-348
Authors:
SHAPIRO JD
ROTHENBERG ML
SAROSY GA
STEINBERG SM
ADAMO DO
REED E
OZOLS RF
KOHN EC
Citation: Jd. Shapiro et al., DOSE-INTENSIVE COMBINATION PLATINUM AND CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH ADVANCED UNTREATED EPITHELIAL OVARIAN-CANCER, Cancer, 83(9), 1998, pp. 1980-1988
Authors:
OZOLS RF
Citation: Rf. Ozols, CONTROVERSIES IN THE MANAGEMENT OF OVARIAN-CANCER, International journal of gynecological cancer, 7, 1997, pp. 27-32
Authors:
BOOKMAN MA
KLOTH DD
KOVER PE
SMOLINSKI S
OZOLS RF
Citation: Ma. Bookman et al., SHORT-COURSE INTRAVENOUS PROPHYLAXIS FOR PACLITAXEL-RELATED HYPERSENSITIVITY REACTIONS, Annals of oncology, 8(6), 1997, pp. 611-614
Authors:
OZOLS RF
Citation: Rf. Ozols, TREATMENT OF RECURRENT OVARIAN-CANCER - INCREASING OPTIONS - RECURRENT RESULTS, Journal of clinical oncology, 15(6), 1997, pp. 2177-2180
Authors:
OREILLY S
FLEMING GF
BAKER SD
WALCZAK JR
BOOKMAN MA
MCGUIRE WP
SCHILDER RJ
ALVAREZ RD
ARMSTRONG DK
HOROWITZ IR
OZOLS RF
ROWINSKY EK
Citation: S. Oreilly et al., PHASE-I TRIAL AND PHARMACOLOGICAL TRIAL OF SEQUENCES OF PACLITAXEL AND TOPOTECAN IN PREVIOUSLY TREATED OVARIAN EPITHELIAL MALIGNANCIES - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 15(1), 1997, pp. 177-186
Authors:
BOOKMAN MA
KLOTH DD
KOVER PE
SMOLINSKI S
OZOLS RF
Citation: Ma. Bookman et al., INTRAVENOUS PROPHYLAXIS FOR PACLITAXEL-RELATED HYPERSENSITIVITY REACTIONS, Seminars in oncology, 24(6), 1997, pp. 13-15
Authors:
OZOLS RF
Citation: Rf. Ozols, FUTURE-DIRECTIONS IN THE CHEMOTHERAPY OF OVARIAN-CANCER, Seminars in oncology, 24(5), 1997, pp. 86-90
Authors:
OZOLS RF
VERMORKEN JB
Citation: Rf. Ozols et Jb. Vermorken, CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - CURRENT STATUS AND FUTURE-DIRECTIONS, Seminars in oncology, 24(1), 1997, pp. 1-9
Authors:
OZOLS RF
Citation: Rf. Ozols, GYNECOLOGIC-ONCOLOGY-GROUP TRIALS IN OVARIAN-CARCINOMA, Seminars in oncology, 24(1), 1997, pp. 10-12
Authors:
JOHNSON SW
LAUB PB
BEESLEY JS
OZOLS RF
HAMILTON TC
Citation: Sw. Johnson et al., INCREASED PLATINUM-DNA DAMAGE TOLERANCE IS ASSOCIATED WITH CISPLATIN RESISTANCE AND CROSS-RESISTANCE TO VARIOUS CHEMOTHERAPEUTIC-AGENTS IN UNRELATED HUMAN OVARIAN-CANCER CELL-LINES, Cancer research, 57(5), 1997, pp. 850-856
Authors:
OBASAJU CK
JOHNSON SW
ROGATKO A
KILPATRICK D
BRENNAN JM
HAMILTON TC
OZOLS RF
ODWYER PJ
GALLO JM
Citation: Ck. Obasaju et al., EVALUATION OF CARBOPLATIN PHARMACOKINETICS IN THE ABSENCE AND PRESENCE OF PACLITAXEL, Clinical cancer research, 2(3), 1996, pp. 549-552
Authors:
OZOLS RF
Citation: Rf. Ozols, PACLITAXEL (TAXOL(R)) PLUS CARBOPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED OVARIAN-CANCER, International journal of gynecological cancer, 6, 1996, pp. 9-12
Authors:
SCHRODER CP
GODWIN AK
ODWYER PJ
TEW KD
HAMILTON TC
OZOLS RF
Citation: Cp. Schroder et al., GLUTATHIONE AND DRUG-RESISTANCE, Cancer investigation, 14(2), 1996, pp. 158-168
Authors:
ESSAYAN DM
KAGEYSOBOTKA A
LICHTENSTEIN LM
COLARUSSO PJ
OZOLS RF
KING ED
Citation: Dm. Essayan et al., PACLITAXEL HYPERSENSITIVITY REVISITED, Journal of clinical oncology, 14(3), 1996, pp. 1042-1042
Authors:
BOOKMAN MA
OZOLS RF
Citation: Ma. Bookman et Rf. Ozols, FACTORING OUTCOMES IN OVARIAN-CANCER, Journal of clinical oncology, 14(2), 1996, pp. 325-327
Authors:
ODWYER PJ
HAMILTON TC
LACRETA FP
GALLO JM
KILPATRICK D
HALBHERR T
BRENNAN J
BOOKMAN MA
HOFFMAN J
YOUNG RC
COMIS RL
OZOLS RF
Citation: Pj. Odwyer et al., PHASE-I TRIAL OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALANIN PATIENTS WITH CANCER, Journal of clinical oncology, 14(1), 1996, pp. 249-256
Authors:
HAGEBOUTROS A
HUDES GR
BRENNAN J
GREEN F
HOFFMAN J
LACRETA FP
COLOFIORE J
MARTIN DS
OZOLS RF
ODWYER PJ
Citation: A. Hageboutros et al., PHASE-I TRIAL OF FLUOROURACIL MODULATION BY N-PHOSPHONACETYL-L-ASPARTATE AND 6-METHYLMERCAPTOPURINE RIBONUCLEOSIDE, Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 229-234
Authors:
ESSAYAN DM
KAGEYSOBOTKA A
COLARUSSO PJ
LICHTENSTEIN LM
OZOLS RF
KING ED
Citation: Dm. Essayan et al., SUCCESSFUL PARENTERAL DESENSITIZATION TO PACLITAXEL, Journal of allergy and clinical immunology, 97(1), 1996, pp. 42-46
Authors:
JOHNSON SW
LISSY NA
MILLER PD
TESTA JR
OZOLS RF
HAMILTON TC
Citation: Sw. Johnson et al., IDENTIFICATION OF ZINC-FINGER MESSENGER-RNAS USING DOMAIN-SPECIFIC DIFFERENTIAL DISPLAY, Analytical biochemistry, 236(2), 1996, pp. 348-352
Authors:
ODWYER PJ
HAMILTON TC
YAO KS
TEW KD
OZOLS RF
Citation: Pj. Odwyer et al., MODULATION OF GLUTATHIONE AND RELATED ENZYMES IN REVERSAL OF RESISTANCE TO ANTICANCER DRUGS, Hematology/oncology clinics of North America, 9(2), 1995, pp. 383-396
Authors:
OZOLS RF
Citation: Rf. Ozols, USA UPDATE ON PACLITAXEL IN OVARIAN-CANCER, Annals of medicine, 27(1), 1995, pp. 127-130
Authors:
LANGER CJ
LEIGHTON JC
COMIS RL
ODWYER PJ
MCALEER CA
BONJO CA
ENGSTROM PF
LITWIN S
OZOLS RF
Citation: Cj. Langer et al., PACLITAXEL AND CARBOPLATIN IN COMBINATION IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II TOXICITY, RESPONSE, AND SURVIVAL ANALYSIS, Journal of clinical oncology, 13(8), 1995, pp. 1860-1870
Authors:
HAGEBOUTROS A
ROGATKO A
NEWMAN EM
MCALEER C
BRENNAN J
LACRETA FP
HUDES GR
OZOLS RF
ODWYER PJ
Citation: A. Hageboutros et al., PHASE-I STUDY OF PHOSPHONACETYL-L-ASPARTATE, 5-FLUOROURACIL, AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 205-212